1.12

2.61% -0.03

After Hours: 1.11 -0.01 -0.89%

NanoViricides Inc (NNVC)

Overview News Price History Option Chain Discussions Forecast Stock Split

NanoViricides Inc stock is traded at $1.12, with a volume of 486.90K. It is down -2.61% in the last 24 hours and down -26.32% over the past month. NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could provide functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.

Previous Close:

$1.15

Open:

$1.15

24h Volume:

486.90K

Relative Volume:

1.42

Market Cap:

$28.56M

Revenue:

Net Income/Loss:

$-8.09M

P/E Ratio:

-2.5723

EPS:

-0.4354

Net Cash Flow:

$-7.37M

1W Performance:

-9.68%

1M Performance:

-26.32%

6M Performance:

+17.13%

1Y Performance:

-18.55%

1-Day Range:

$1.10

$1.17

1-Week Range:

$1.10

$1.33

52-Week Range:

$0.85

$2.2299

NanoViricides Inc Stock (NNVC) Company Profile

Name

NanoViricides Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

203-937-6137

Address

1 Controls Drive, Shelton, CT

Employee

Twitter

@nnvcnyse

Next Earnings Date

2026-10-05

Latest SEC Filings

NNVC's Discussions on Twitter

Compare NNVC vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NNVC NanoViricides Inc	1.12	33.40M	0	-8.09M	-7.37M	-0.4354
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

NanoViricides Inc Stock (NNVC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-16-25	Initiated	Alliance Global Partners	Buy
Feb-11-15	Initiated	Midtown Partners	Strong Buy

NanoViricides Inc Stock (NNVC) Latest News

Sep 06, 2026

While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles - ACCESS Newswire

Sep 06, 2026

NNVC Stock In The Limelight After This Analyst Sees A 350% Upside Potential – Everything To Know About Its Experimental Drug For Ebola - Stocktwits

Sep 06, 2026

Sep 04, 2026

Nanoviricides Stock Price Forecast. Should You Buy NNVC? - StockInvest.us

Sep 04, 2026

Sep 03, 2026

NanoViricides (AMEX: NNVC) May Generate Up to $4.4 Million Through Warrant Exercises - Kalkine Media

Sep 03, 2026

Sep 01, 2026

US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for MeaslesEnables Priority Review Voucher - ACCESS Newswire

Sep 01, 2026

Aug 31, 2026

U.S. measles cases reach 2,903 by Aug. 27 as NanoViricides prepares a trial - Stock Titan

Aug 31, 2026

Aug 27, 2026